GENE ONLINE|News &
Opinion
Blog

2021-09-01| Trials & Approvals

AC Immune’s Stock Climbs Following Mixed Phase 2 Trial Results for Alzheimer’s Disease Drug

by Daniel Ojeda
Share To

Alzheimer’s disease (AD) treatments have received a lot of attention this year after the historic and controversial approval of Aduhelm by the FDA. The therapy was approved based on two Phase 3 clinical trials, the results of which are hotly disputed in the community. However, only in one of the trials, Aduhelm reduced cognitive decline. The treatment successfully reduced the levels of amyloid-beta, a protein that accumulates in the brains of AD patients.

The approval was met with controversy because of a lack of clear benefits for the patients and the high cost of the drug. Currently priced at $56,000 a year, the cost has led insurers to announce they would not cover the drug. Medicare has now begun a national review to determine conditions for nationwide coverage. If met with an unfavorable decision, patients might not be reimbursed for the treatment. 

New therapies for AD are necessary since there is a large unmet need. Additionally, the number of people aged 65 and older with AD is expected to grow past 10 million over the next decades. For this reason, the AD community is eager for new therapeutic options, and companies are racing to develop them.

Although a lot of attention is given to amyloid-beta, another top suspect in AD disease is the Tau protein, which accumulates in the brain and forms tangles damaging the neurons. AC Immune, a Switzerland-based company, has developed a monoclonal antibody, semorinemab, to bind to tau and slow its spread between neurons.

On August 31st, AC Immune announced that semorinemab met one of its primary endpoints of a Phase 2 trial, reducing cognitive decline by 43.6% compared to placebo as measured by a cognitive test.  The news sent its stock more than 70% higher at the opening bell. At the end of the session, the stock was still 18.7% higher than the previous session.

Related Article: Poseida Presents Encouraging Preliminary Data for Autologous CAR-T Candidate Against Solid Tumors

 

Promising Results From Phase 2 Lauriet Trial

AC Immune specializes in developing precision medicines for neurodegenerative diseases. Their pipeline includes several diagnostic compounds and therapeutics in clinical trials. Two of their most advanced products include a monoclonal antibody-based therapy and a vaccine, both against amyloid-beta. Both candidates are now in Phase 2 trials.

Another therapeutic target being investigated by AC Immune, in collaboration with Genentech, is semorinemab, their anti-tau antibody. In the Phase 2 Lauriet trial, semorinemab successfully reduced cognitive decline at week 49 as measured by the Alzheimer’s Disease Assessment Scale, Cognitive Subscale, 11-item Version (ADAS-Cog11) in patients with mild-to-moderate AD.

The therapy did not meet its second co-primary endpoint of reducing cognitive decline as measured by a different test, and it did not meet its secondary endpoints. Additionally, the antibody was well tolerated. The open-label portion of the study will continue as planned.

Prof. Andrea Pfeifer, CEO of AC Immune, expressed guarded excitement over the results.

“The top-line results of the Lauriet Phase 2 clinical trial of semorinemab are remarkable in that it is the first time we have seen a therapeutic effect by a monoclonal anti-Tau antibody therapy. We also are excited by the fact that this is the first time a monoclonal antibody has had a therapeutic impact on cognition in the mild-to-moderate AD patient population,” he said.

“Nevertheless, despite these interesting results, we are still cautious about what this may mean for patients as there was not an impact on the rate of functional decline or other efficacy endpoints…” he added.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top